Search Result

Results for "

δ-opioid receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Opioid Receptor (26) Angiotensin-converting Enzyme (ACE) (1) Drug Metabolite (1) Endogenous Metabolite (1) Flavivirus (1) Fluorescent Dye (1) Isotope-Labeled Compounds (3)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (1) Metabolic Disease (1) Neurological Disease (25)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Opioid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123689

Samidorphan ALKS-33; RDC-0313	Opioid Receptor	Neurological Disease
Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-13243

Alvimopan ADL 8-2698; LY 246736	Opioid Receptor	Neurological Disease
Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and **δ-opioid receptors (K_i**s=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

HY-163895

δ opioid receptor antagonist 1	Fluorescent Dye Opioid Receptor	Neurological Disease
δ opioid receptor antagonist 1 (compound 6-Cy3) is a fluorescent antagonist probe with high selectivity for δ opioid receptor (DOR) (K_i=1.7 nM). δ opioid receptor antagonist 1 can be used to study the mechanism of pain perception .

HY-107745

SDM25N hydrochloride	Opioid Receptor Flavivirus	Infection Neurological Disease
SDM25N hydrochloride, a **δ-opioid receptor** antagonist, is a potent DENV inhibitor. SDM25N hydrochloride targets the viral NS4B protein and restricts genomic RNA replication .

HY-10486

JDTic	Opioid Receptor	Neurological Disease
JDTic is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

HY-123689A

Samidorphan hydrochloride ALKS-33 hydrochloride; RDC-0313 hydrochloride	Opioid Receptor	Neurological Disease
Samidorphan hydrochloride is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan hydrochloride acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan hydrochloride primarily acts as an opioid receptor antagonist in vivo .

HY-123689S

Samidorphan-d4 ALKS-33-d₄; RDC-0313-d₄	Isotope-Labeled Compounds	Neurological Disease
Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-123689S1

Samidorphan-d5 ALKS-33-d₅; RDC-0313-d₅	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active *opioid* system modulator that binds with high affinity to *μ-opioid, κ-opioid, and δ-opioid* receptors. Samidorphan is a *μ-opioid* receptor antagonist and a partial agonist at *k-opioid* and *δ-opioid* receptors. Samidorphan acts primarily as an *opioid* receptor antagonist in vivo .

HY-101199

N-Benzylnaltrindole hydrochloride	Opioid Receptor	Neurological Disease
N-Benzylnaltrindole hydrochloride is a potent δ2-selective opioid receptor antagonist. Benzylnaltrindole hydrochloride has a long duration of action in vivo than Naltriben (NTB). N-Benzylnaltrindole hydrochloride iserve as a useful tool in the pharmacologic characterization of δ-opioid receptor function .

HY-P2429

N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu	Opioid Receptor	Others
N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu is a compound that can antagonize the δ-opioid receptor and the action of [D-Pen2,D-Pen?] enkephalin in vivo. Its antagonistic effect can be verified by specific behavioral experiments.

HY-76657

Alvimopan monohydrate ADL 8-2698 monohydrate; LY 246736 monohydrate	Opioid Receptor	Neurological Disease Cancer
Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan monohydrate has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and **δ-opioid receptors (K_i**s=100, 12 nM, respectively). Alvimopan monohydrate can be used for the research of postoperative ileus .

HY-76657A

Alvimopan dihydrate ADL 8-2698 dihydrate; LY 246736 dihydrate	Opioid Receptor	Neurological Disease Cancer
Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and **δ-opioid receptors (K_i**s=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-P2669

Boc-YPGFL(O-tBu)	Opioid Receptor	Neurological Disease
Boc-YPGFL(O-tBu) is a selective δ opioid receptor (DOR) peptide antagonist .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a **delta-opioid receptor** antagonist and can be used for seizure research.

HY-11052A

Trap-101 hydrochloride	Opioid Receptor	Neurological Disease
Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ ³⁵S binding to CHO_hNOP membranes with pK_i values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases .

HY-129422

Diallyl G	Opioid Receptor	Neurological Disease
Diallyl G is a **delta-opioid receptor** antagonist. Diallyl G shows inhibitory effect on GTPase .

HY-13243S1

Alvimopan-d7 ADL 8-2698-d₇; LY 246736-d₇	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease Cancer
Alvimopan-d₇ (ADL 8-2698-d₇) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and **δ-opioid receptors (K_i**s=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

HY-A0115R

Ramiprilat (Standard)	Drug Metabolite Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-76657AR

Alvimopan (dihydrate) (Standard)	Opioid Receptor	Neurological Disease Cancer
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-136208

TAN-452	Opioid Receptor	Neurological Disease
TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a K_i of 0.47 nM and a K_b of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; K_i=36.56 nM and K_b=9.43 nM) and κ-opioid receptor (KOR; K_i=5.31 nM and K_b=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and **δ opioid receptors*, and an antagonist* at **opioid-like NOP receptors**. Naloxone benzoylhydrazone has potently analgesia effect .

HY-106732

AT-076	Opioid Receptor	Neurological Disease
AT-076 is an opioid pan antagonist at nociception, kappa, mu, and *delta opioid* receptors, with K_i values of 1.75 nM (NOP), 1.67 nM (MOP), 1.14 nM (KOP) and 19.6 nM (DOP), respectively .

HY-117881

CJ-15208	Opioid Receptor	Neurological Disease
CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics .

HY-118615

LY2048978	Opioid Receptor	Neurological Disease
LY2048978 is a non-selective **opioid receptor** antagonist with K_i of 0.287, 0.471 and 1.05 nM for human mu, kappa and delta opioid receptors in vitro, respectively. LY2048978 can be used in the research of major depressive disorder and alcohol use disorder .

HY-172149

Naltrindole 5′-isothiocyanate 5'-NTII	Opioid Receptor	Neurological Disease
Naltrindole 5′-isothiocyanate (5'-NTII) is a non-selective delta opioid *receptor* antagonist that can antagonize the analgesic effects induced by DSLET (HY-P1332) without affecting the analgesic effects induced by DPDPE (HY-P1334) .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over *δ opioid* (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over *δ opioid* (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-101317A

TAN-67 SB-205607	Opioid Receptor	Metabolic Disease
TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.

Cat. No.	Product Name	Target	Research Area

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over *δ opioid* (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P2429

N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu	Opioid Receptor	Others
N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu is a compound that can antagonize the δ-opioid receptor and the action of [D-Pen2,D-Pen?] enkephalin in vivo. Its antagonistic effect can be verified by specific behavioral experiments.

HY-P2669

Boc-YPGFL(O-tBu)	Opioid Receptor	Neurological Disease
Boc-YPGFL(O-tBu) is a selective δ opioid receptor (DOR) peptide antagonist .

HY-129422

Diallyl G	Opioid Receptor	Neurological Disease
Diallyl G is a **delta-opioid receptor** antagonist. Diallyl G shows inhibitory effect on GTPase .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over *δ opioid* (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0115R

Ramiprilat (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Source classification Endogenous metabolite	Drug Metabolite Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

Cat. No.	Product Name	Chemical Structure

HY-123689S

Samidorphan-d4
Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-123689S1

Samidorphan-d5
Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active *opioid* system modulator that binds with high affinity to *μ-opioid, κ-opioid, and δ-opioid* receptors. Samidorphan is a *μ-opioid* receptor antagonist and a partial agonist at *k-opioid* and *δ-opioid* receptors. Samidorphan acts primarily as an *opioid* receptor antagonist in vivo .

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-13243S1

Alvimopan-d7
Alvimopan-d₇ (ADL 8-2698-d₇) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and **δ-opioid receptors (K_i**s=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

Alvimopan-d7

Alvimopan-d₇ (ADL 8-2698-d₇) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks